Literature DB >> 26067724

Novel technique for cranial reconstruction following retrosigmoid craniectomy using demineralized bone matrix.

Aqueel H Pabaney1, Kevin A Reinard2, Karam Asmaro2, Ghaus M Malik2.   

Abstract

OBJECTIVE: A versatile neurosurgical approach, the retrosigmoid craniectomy (RS) has traditionally been associated with high rates of post-operative cerebrospinal fluid (CSF) leak, headaches, and aesthetic defects. We introduce a simple surgical strategy for bony cranial reconstruction designed to minimize peri-operative complications and improve cosmetic outcomes.
METHODS: In accordance with the Institutional Review Board, the senior author's (G.M.M.) records were queried between 2006 and 2014. We identified 50 consecutive patients who underwent demineralized bone matrix (DBM)-augmented cranioplasty after RS for MVD (DBM group) and 92 consecutive patients in whom standard cranial reconstruction was undertaken using autologous bone chips only after RS for MVD (non-DBM group). Demographic and clinical information regarding the laterality of each operation, intra-dural drilling for petrous hyperostosis, method of dural closure, length of hospitalization, presence of post-operative headaches, and procedure-related complications were collected and analyzed.
RESULTS: The DBM and non-DBM cohorts were well matched for age, laterality of procedure, surgical indications, primary versus revision surgery, intra-dural drilling of petrous hyperostosis, and dural closure techniques. Trigeminal neuralgia was the most common surgical indication (98.6%) in each cohort. Post-operatively, 15% of patients in non-DBM group experienced chronic headaches at the last follow-up compared to only 8% of the patients in the DBM group (p=0.21). The non-DBM patients also suffered more incisional pain in comparison to the DBM patients (7.6% vs. 0%, p=0.045).
CONCLUSION: DBM-augmented reconstruction of posterior fossa defects resulted in low rates of post-operative headaches, better cosmetic outcomes, and represents a simple and effective cranioplasty option for skull base surgeons.
Copyright © 2015 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CSF leak; Cranial defect; Cranioplasty; Demineralized bone matrix; Headaches; Microvascular decompression; Retrosigmoid craniectomy

Mesh:

Substances:

Year:  2015        PMID: 26067724     DOI: 10.1016/j.clineuro.2015.05.034

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  5 in total

Review 1.  Complications and cosmetic outcomes of materials used in cranioplasty following decompressive craniectomy-a systematic review, pairwise meta-analysis, and network meta-analysis.

Authors:  Jakob V E Gerstl; Luis F Rendon; Shane M Burke; Joanne Doucette; Rania A Mekary; Timothy R Smith
Journal:  Acta Neurochir (Wien)       Date:  2022-05-20       Impact factor: 2.216

2.  Retrosigmoid Craniectomy with a Layered Soft Tissue Dissection and Hydroxyapatite Reconstruction: Technical Note, Surgical Video, Regional Anatomy, and Outcomes.

Authors:  Stephen T Magill; Young M Lee; Roberto R Rubio; Minh P Nguyen; Carl B Heilman; Michael W McDermott
Journal:  J Neurol Surg B Skull Base       Date:  2021-02-22

3.  Demineralized bone matrix used for direct pulp capping in rats.

Authors:  Qian Liu; Yanhong Ma; Junlan Wang; Xuefang Zhu; Yanjing Yang; Yufeng Mei
Journal:  PLoS One       Date:  2017-03-02       Impact factor: 3.240

Review 4.  A Narrative Review of Cell-Based Approaches for Cranial Bone Regeneration.

Authors:  Maria I Falguera Uceda; Silvia Sánchez-Casanova; Clara Escudero-Duch; Nuria Vilaboa
Journal:  Pharmaceutics       Date:  2022-01-05       Impact factor: 6.321

5.  Factors associated with cerebrospinal fluid leak after a retrosigmoid approach for cerebellopontine angle surgery.

Authors:  Nicola Montano; Francesco Signorelli; Martina Giordano; Federica Ginevra D'Onofrio; Alessandro Izzo; Manuela D'Ercole; Eleonora Ioannoni; Giovanni Pennisi; Anselmo Caricato; Roberto Pallini; Alessandro Olivi
Journal:  Surg Neurol Int       Date:  2021-06-07
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.